Delivery Order SPE2DB25D3001-SPE2DB25FQVAL
- Not listed
- The Defense Logistics Agency awarded a $2,090.75 delivery order to AmerisourceBergen Drug Corp for supply of Dupixent 300 mg/2 ml syringes on July 30, 2025. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of July 31, 2025. The pharmaceutical product will be delivered to the company's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 mL syringes on June 18, 2025, with an ultimate completion date of June 20, 2025. This firm fixed-price, non-set-aside contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract...
- The Defense Logistics Agency awarded a delivery order valued at $17,094.60 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for supply of Dupixent (dupilumab) 300 mg/2 ml syringes on September 12, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order, valued at $1,709.46, was awarded without a set-aside designation through competitive procurement. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $11,735.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on July 30, 2025, with an ultimate completion date of July 31, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $10,777.92 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $45,274.14 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes on August 27, 2025, with a completion date of August 28, 2025. This contract utilizes a firm fixed-price delivery order structure with no set-aside designation, indicating competitive award through open procurement channels. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Dupixent 300 mg/2 mL syringes with a ceiling value of $1,709.46. This is a firm fixed-price delivery order with an ultimate completion date of August 19, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB25D3001Indefinite Delivery Contract
- SPE2DB25D3001-SPE2DB25FQVALDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml syringes on August 4, 2025, with completion scheduled for August 5, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. This comprehensive pharmaceutical prime vendor contract enables AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare systems globally, including the Defense Health Agency and U.S. Coast Guard. Dupixent, a biologic immunosuppressant used to treat conditions such as atopic dermatitis, eczema, and asthma, represents a specialty medication within the company's extensive portfolio of brand-name and generic pharmaceuticals delivered to federal medical procurement customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/4/25 |